Retinal protein aggregates as biomarkers in Alzheimer’s and Parkinson’s disease.

Using 7-Tesla MRI to study cerebral impacts of COVID-19 infection

APOE-induced lipid changes and Alzheimer’s disease pathogenesis

PET imaging of reactive astrogliosis in Alzheimer’s disease

Using neuropsychiatric symptoms as clinical markers for dementia diagnosis

Prioritizing diversity in Alzheimer’s disease biomarker studies

Late-life major depression impacts plasma Aβ dynamics

Use of machine learning to identify signs of cognitive decline

Multi-PET tracers reveal the complex nature of 4R tauopathies

Biomarkers in DLB trials

Natural killer cell integrity within Alzheimer’s disease

Immune activation states in Alzheimer’s disease mouse models

AI with advanced retinal imaging techniques to detect neurodegenerative disease risk markers

Measuring cognitive impairment in early Alzheimer’s disease

Gut microbiome composition and cognitive function in middle-aged adults

Treating patients with hearing loss and cognitive impairment